CHF44.85
1.47% day before yesterday
SIX Swiss Exchange, May 02, 05:30 pm CET
ISIN
CH0011432447
Symbol
BSLN
Sector
Industry

Basilea Pharmaceutica Stock price

CHF44.85
+1.40 3.22% 1M
+1.20 2.75% 6M
+3.50 8.46% YTD
+5.25 13.26% 1Y
+13.00 40.82% 3Y
-3.51 7.26% 5Y
-71.05 61.30% 10Y
SIX Swiss Exchange, Closing price Fri, May 02 2025
+0.65 1.47%
ISIN
CH0011432447
Symbol
BSLN
Sector
Industry

Key metrics

Market capitalization CHF544.04m
Enterprise Value CHF531.15m
P/E (TTM) P/E ratio 7.00
EV/FCF (TTM) EV/FCF 7.31
EV/Sales (TTM) EV/Sales 2.55
P/S ratio (TTM) P/S ratio 2.61
P/B ratio (TTM) P/B ratio 6.72
Revenue growth (TTM) Revenue growth 32.30%
Revenue (TTM) Revenue CHF208.54m
EBIT (operating result TTM) EBIT CHF61.18m
Free Cash Flow (TTM) Free Cash Flow CHF72.65m
EPS (TTM) EPS CHF6.40
P/E forward 14.66
P/S forward 2.50
EV/Sales forward 2.45
Show more

Is Basilea Pharmaceutica a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,786 stocks worldwide.

Basilea Pharmaceutica Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Basilea Pharmaceutica forecast:

3x Buy
75%
1x Hold
25%

Analyst Opinions

4 Analysts have issued a Basilea Pharmaceutica forecast:

Buy
75%
Hold
25%

Financial data from Basilea Pharmaceutica

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Dec '24
+/-
%
209 209
32% 32%
100%
- Direct Costs 39 39
44% 44%
19%
170 170
30% 30%
81%
- Selling and Administrative Expenses 28 28
8% 8%
13%
- Research and Development Expense 77 77
1% 1%
37%
65 65
185% 185%
31%
- Depreciation and Amortization 3.53 3.53
1% 1%
2%
EBIT (Operating Income) EBIT 61 61
219% 219%
29%
Net Profit 78 78
642% 642%
37%

In millions CHF.

Don't miss a Thing! We will send you all news about Basilea Pharmaceutica directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Basilea Pharmaceutica AG engages in the development and commercialization of pharmaceutical products. Its products include antifungals and antibiotics. The company was founded on October 17, 2000, and is headquartered in Allschwil, Switzerland.

Head office Switzerland
CEO David Veitch
Employees 164
Founded 2000
Website www.basilea.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today